Maggie is a senior editor for The American Journal of Managed Care® (AJMC®) and produces written, video, and podcast content covering several disease states. She joined AJMC® in 2019, and has been with AJMC®’s parent company, MJH Life Sciences®, since 2014, when she started as a copy editor.
She has a BA in English from Penn State University. You can connect with Maggie on LinkedIn.
Understanding How Complement C5 Inhibitors Work in MG: Miriam Freimer, MD
In myasthenia gravis, complement plays a big role in what happens to the muscle end of the neuromuscular junction, explains Miriam Freimer, MD, an author on 5 abstracts presented at the recent 15th MGFA International Conference on Myasthenia and Related Disorders.
Atrasentan Has Promising Long-Term Potential in IgA Nephropathy: Richard Lafayette, MD, FACP
Richard Lafayette, MD, FACP, explains why a REMS program is not required for the endothelin A receptor antagonist and how patients may need to adjust should final ALIGN trial data fail to show a clinical benefit of atrasentan.
Targeting the Root of gMG With Inebilizumab: A Q&A With Richard Nowak, MD, MS
In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant improvements in patient- and physician-assessed outcomes, as well as longer-term implications and future areas of investigation.
From Red Tape to Relief: Rewriting the Rules of Prior Authorization
Up to 257 million Americans could benefit from these prior authorization reforms that could have cross-market implications on health care plans administered through commercial insurers, Medicare Advantage, and Medicaid.
Culture Key to Data Collection of Sexual Orientation and Gender Identity in Cancer Care
This research highlights the key factors, like leadership buy-in, mandatory protocols, and electronic health record workflows, that influence the effective collection of data on sexual orientation and gender identity in outpatient oncology clinics to improve patient-centered care.
Breaking Down Taletrectinib’s FDA Approval: Jorge J. Nieva, MD
In this interview with TRUST-I and TRUST-II trial investigator, Jorge J. Nieva, MD, USC Keck School of Medicine, he walks through the design of the trials, the results that supported the FDA approval, and taletrectinib’s potential to redefine first-line therapy.
CARTITUDE-4 Data Solidify Cilta-cel’s Role in RRMM: Surbhi Sidana, MD, MBBS
Surbhi Sidana, MD, MBBS, director of the Myeloma Disease Focused Group at Stanford University, provides a reintroduction to CARTITUDE-4 and insight on how this phase 3 investigation builds on previous findings of CAR T vs standard-of-care findings in relapsed/refractory multiple myeloma (RRMM)
DVRd vs VRd in Transplant-Ineligible Myeloma: Insights From Saad Z. Usmani, MD, MBA
CEPHEUS trial lead investigator Saad Z. Usmani, MD, MBA, FACP, FASCO, explains how the trial both builds on current knowledge of newly diagnosed multiple myeloma and how transplant-ineligible status may affect therapeutic decision-making.
COVID-19’s Hidden Toll: Noah Greenspan, DPT, on Inflammation, Flares, and Recovery
Noah Greenspan, DPT, PT, CCS, EMT-B, cardiopulmonary physical therapist and director of the Pulmonary Wellness and Rehabilitation Center in New York City, reflects on how the reality of COVID-19 infection proved far more complex than initially thought.
Pediatric Atopic Dermatitis Linked to Allergy Development
Outcomes were evaluated among children born between April 1980 and June 2019 by using data from 12 observational birth cohorts from the Environmental Influences on Child Health Outcomes Children’s Respiratory and Environmental Workgroup.
Addressing Myasthenia Gravis Diagnostic Delays and Access Barriers: Marla Black Morgan, MD
Marla Black Morgan, MD, looks to the future of research in both myasthenia gravis and rare neurological disorders by expanding data collection and identifying areas of potential difference in patient outcomes.
Zilucoplan Shows Rapid, Durable, Steroid-Sparing Benefits in gMG
Zilucoplan (Zilbrysq; UCB) is a once-daily subcutaneous C5 complement inhibitor that has demonstrated long-term treatment benefits in patients who have acetylcholine receptor antibody–positive generalized myasthenia gravis (gMG).
Rusfertide Offers Sustainable PV Management Strategy: Andrew Kuykendall, MD
Andrew Kuykendall, MD, Moffitt Cancer Center, explains the goals of the VERIFY trial and why its data on rusfertide could have paradigm-changing implications for patients with polycythemia vera (PV) who currently rely on frequent phlebotomies for relief.
New Insights Into Meth-Associated PAH Care Gaps: Anjali Vaidya, MD, on Closing the Divide
Research from Anjali Vaidya, MD, FACC, FASE, FACP, Temple University Hospital, reveals critical care gaps for patients with methamphetamine-associated pulmonary arterial hypertension (PAH), emphasizing the need for early diagnosis and integrated support.
Expanding Hope for Pediatric Myasthenia Gravis: Jonathan Strober, MD
In this final part of a recent interview with Jonathan Strober, MD, UCSF Benioff Children's Hospital and phase 2/3 Vibrance-MG study investigator, he explains the difficulty of evaluating investigative treatments for pediatric patients who have myasthenia gravis.